Drug Research

WCG’s MedAvante-ProPhase Adds Business Leaders to Expand Offerings, Increase Client Success in CNS, Mental Health

August 16, 2017

Industry experts will help to drive company’s growth in central nervous system (CNS) and behavioral health assessment markets WIRB-Copernicus Group® (WCG™), the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, announced today that industry experts Steven Herne and Michael Cioffi have joined the leadership of MedAvante-ProPhase, the Group’s electronic […]

Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100

August 15, 2017

SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the peer-reviewed publication of non-clinical data describing the unique properties and anti-tumor activity of FATE-NK100, the Company’s first-in-class adaptive memory natural killer (NK) cell […]

BioreclamationIVT Acquires Biospecimen and Research Services Provider Asterand Bioscience

August 15, 2017

Acquisition broadens BioreclamationIVT’s disease-state biospecimen capabilities, particularly in oncology, and expands its scientific service offerings for diagnostic and drug development researchers BioreclamationIVT, a leading provider of biospecimens and related services, today announced that it has acquired Asterand Bioscience™, a global provider of high quality, well-characterized human tissue and research solutions with a focus on the […]

Study Hints at Experimental Therapy for Heart Fibrosis

August 15, 2017

CINCINNATI, Aug. 14, 2017 /PRNewswire-USNewswire/ — Researchers report encouraging preclinical results as they pursue elusive therapeutic strategies to repair scarred and poorly functioning heart tissues after cardiac injury – describing an experimental molecular treatment for heart failure.   In a study posted online Aug. 14 by Journal of the American College of Cardiology, researchers at […]

Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors

August 15, 2017

TÜBINGEN, Germany and BOSTON, Aug. 15, 2017 /PRNewswire/ — CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced the publication of a study in the peer-reviewed journal EMBO Molecular Medicine, demonstrating the utility of CureVac’s RNAntibody® technology as a potent novel approach for passive immunization and a potentially ideal platform for applications where […]

Certara Introduces Externalization Technology to its D360 Scientific Informatics Platform

August 15, 2017

D360 Partner™ Provides Secure Data Access and Facilitates Collaboration on Drug Discovery Projects between Pharmaceutical Research Teams at Multiple Organizations Certara®, the global leader in model-informed drug development and regulatory science, today announced that it has added externalization technology to its D360 scientific informatics platform. The resulting new product, D360 Partner, facilitates collaboration between sponsors […]

2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121

August 11, 2017

CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) — 2X Oncology, Inc. (“2X” or the “Company”), a precision medicine company developing targeted therapeutics to address significant unmet needs in women’s cancer, today announced the successful validation of the Drug Response Predictor (DRP™) for 2X-121, its Phase 2 PARP inhibitor recently licensed from Eisai. “It is of […]

Moleculin Comments on Recent FDA Drug Approvals for Acute Myeloid Leukemia

August 9, 2017

HOUSTON, TX–(Marketwired – August 09, 2017) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today commented on several recent […]

The Future of RWE Technology – Moving Beyond Rapid Cycle Analytics

August 7, 2017

In recent years, a plethora of real-world evidence (RWE) analytic platforms have emerged, giving researchers the ability to submit analysis parameters, execute analytic programs across specific data sources, and produce rapid results without custom programming. These RWE platforms facilitate shortened analysis cycle times, delivering results in minutes or hours, instead of days, weeks, or longer. […]

WuXi’s Pharmaceutical Development Services Division Merges with STA

August 7, 2017

Shanghai, July 31, 2017: STA Pharmaceutical Co., Ltd. (STA) – a WuXi AppTec group company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing – announces that it has merged with WuXi AppTec’s Pharmaceutical Development Services (PDS) division. The PDS division offers pre-formulation development, formulation development, as well as Clinical […]

PLOS ONE publishes results of cardiac-directed catalytically inactive AC6 in mice after sustained β-adrenergic stimulation

August 4, 2017

SAN DIEGO, Aug. 2, 2017 /PRNewswire-USNewswire/ — Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, today announced publication in PLOS ONE of results of cardiac-directed expression of a mutant form of adenylyl cyclase type 6 (AC6mut). Unlike AC6, AC6mut does not produce cyclic AMP (adenosine monophosphate; cAMP) – […]

Hemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fatigue Syndrome

August 4, 2017

PHILADELPHIA – August 4, 2017 – Hemispherx Biopharma (NYSE : HEB) said today that a new study led by a team of researchers from Stanford University may provide the basis for a long-sought diagnostic to test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), which is estimated to afflict more than one million Americans,according to the U.S. […]

FDA approves leukemia treatment developed by Celgene, Agios

August 3, 2017

Idhifa is the first and only FDA-approved therapy for patients with an IDH2 mutation, a group that accounts for 8 to 19 percent of all AML patients. In the United States, that translates to about 1,200 to 1,500 patients, Celgene said.   (Reuters) – The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene […]

Rising Biosciences, Inc. Initiates Testing for FDA Approval of OTC Chronic Pain Relief Medications

August 3, 2017

NEW YORK, NY–(Marketwired – Aug 2, 2017) – Rising India’s (OTC: RSII) Rising Biosciences, Inc., a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, announces that the Company has entered in the FDA testing phase on its revolutionary medical creams for chronic pain […]

Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC)

August 2, 2017

SAN DIEGO–(BUSINESS WIRE)–Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including anti-infective immunotherapies, today announced publication of data from an in vivo study investigating the deep tissue distribution of CD101, Cidara’s next-generation echinocandin agent, compared to the current first-line treatment, micafungin, in the setting of intra-abdominal candidiasis (IAC), one of the most lethal […]

CrownBio Launches Innovative Inflammatory Disease Models to Advance Pre-Clinical Research

August 2, 2017

SANTA CLARA, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, cardiovascular and metabolic disease research, announces the launch of pre-clinical models of inflammatory bowel disease (IBD) and rheumatoid arthritis […]

Moderna Provides Update on mRNA Rare Disease R&D Strategy

July 28, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, provided an update today on its rare disease Research & Development (R&D) strategy, issuing the following statement related to Alexion Pharmaceuticals, Inc.’s (Nasdaq: ALXN) R&D realignment announcement. […]

Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators

July 27, 2017

SAN DIEGO, July 26, 2017 /PRNewswire/ —   Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB) reported that researchers for Regen BioPharma Inc. have identified what the company believes to be a strong activator for modulating checkpoint NR2F6. This is significant to Zander Therapeutics for two reasons; Zander is the exclusive licensee […]

Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion

July 27, 2017

CAMBRIDGE, Mass., July 27, 2017 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced plans to evaluate opportunities to advance its rare disease discovery program in fibrodysplasia ossificans progressiva (FOP), which was the subject of Blueprint Medicines’ collaboration with Alexion […]

Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications

July 27, 2017

CAMBRIDGE, Mass., July 27, 2017 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the publication of data validating Genethon’s micro-dystrophin gene therapy approach in an animal model for Duchenne muscular dystrophy (DMD). The results were […]

Midatech Pharma Plc: Completion of pre-clinical liver cancer programme

July 26, 2017

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces the successful completion of its pre-clinical programme for its wholly-owned candidate MTD119 (previously MTR104) for advanced liver cancer. The pre-clinical programme included three subcutaneous or orthotopic liver cancer xenograft models treated with the active […]

Researchers identify the component that allows lethal bacteria to spread resistance to antibiotics

July 26, 2017

Barcelona, 26 July 2017.- Antibiotic resistance of the bacterium Staphylococcus aureus is responsible for 11,300 deaths a year in the United States alone—a figure that corresponds to half of all deaths caused by gram-positive resistant bacteria in that country. Such high mortality is related to the speed at which the bacterium acquires resistance to antibiotics. […]

BioreclamationIVT Appoints Vice President of Global Quality and Compliance

July 26, 2017

Karen Sasse brings more than 25 years’ operations and quality management experience to the company BioreclamationIVT, a leading provider of biospecimens and related services, today announced that it has appointed Karen Sasse to the newly-created position of vice president of global quality and compliance. Ms. Sasse will be responsible for the company’s quality assurance and […]

Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases

July 26, 2017

NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (Nasdaq:OPHT) today announced that the Company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. In parallel, the Company continues its ongoing age-related retinal programs and its […]

Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators

July 25, 2017

SAN DIEGO, July 25, 2017 /PRNewswire/ —   Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) today reported continued progress in Regen’s development of small molecule drugs that activate and inhibit NR2F6. The Company reports that recently identified novel chemical compounds that activate NR2F6 also selectively inhibit cytokines secreted from activated immune cells. This indicates […]

Verastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer

July 25, 2017

BOSTON–(BUSINESS WIRE)–Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced scientific findings from studies evaluating focal adhesion kinase (FAK) inhibition in preclinical models of pancreatic and breast cancer with the publication of two papers in the peer-reviewed journals, PLoS One and Oncotarget. […]

NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials

July 25, 2017

CULVER CITY, Calif.–(BUSINESS WIRE)–NantKwest Inc. (Nasdaq:NK), a clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases, today announced a paper entitled “ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 […]

FEEDBACK